Home Industry Reports Custom Research Blogs About Us Contact us

Hepatitis B Vaccine Market Size & Share, by Type (Single Antigen Vaccine, Combination Vaccine), End-use (Hospitals, Clinics) & Regional Forecast, Industry Players, Growth Statistics Report 2024-2033

Report ID: FBI 1617


Published Date: Sep-2023


Format : PDF, Excel

Market Outlook:

Hepatitis B Vaccine Market size exceeded USD 3.47 Billion in 2023 and is anticipated to cross USD 6.56 Billion by 2033, registering a CAGR of more than 5.61 % during the forecast period. The pharmaceutical and healthcare industry's focus on hepatitis B virus (HBV) infection prevention, detection, and treatment is known as the hepatitis B market. A viral infection that targets the liver called hepatitis B can result in both acute and chronic illnesses. Since they have been around for a while, hepatitis B vaccinations are a vital tool in avoiding new infections.

Production, distribution, and administration of these vaccines are all part of the market, as is continuous investigation into better formulations and delivery systems. The management of hepatitis B patients involves the involvement of medical specialists and healthcare organisations. The market covers the distribution of hepatitis B management-related healthcare services as well as the dissemination of treatment recommendations.

Base Year Value (2023)

USD 3.47 Billion

18-23 x.x %
24-33 x.x %

CAGR (2024-2033)


18-23 x.x %
24-33 x.x %

Forecast Year Value (2033)

USD 6.56 Billion

18-23 x.x %
24-33 x.x %
Hepatitis B Vaccine Market

Historical Data Period


Hepatitis B Vaccine Market

Largest Region

North America

Hepatitis B Vaccine Market

Forecast Period


Get more details on this report -

Market Dynamics:

Growth Drivers and Opportunities:

Increase cases of Hepatitis B across the world

The use of hepatitis B vaccinations is essential for stopping the virus's spread. The need for vaccines is projected to expand as the prevalence of Hepatitis B rises, propelling expansion in the pharmaceutical industry. Antiviral drugs are required to treat persistent Hepatitis B infections. Increased research and development in this area may result from higher prevalence, which could result in the approval of new drugs and market growth. Public health authorities may undertake awareness programmes to inform people about Hepatitis B, its transmission, and prevention as the prevalence rises. This might result in more money being allocated to such projects.  Governments may spend money on preventative measures like vaccination efforts, which can benefit pharmaceutical firms.

Rising focus on preventive healthcare

Vaccination is the key to preventing Hepatitis B. Vaccines against hepatitis B have been around for a while and have shown to be very effective. Numerous groups are targeted by vaccination campaigns, including children, teenagers, healthcare professionals, and people who are particularly vulnerable, such as those who use injectable medicines or have multiple partners in a sexual relationship. Campaigns to raise public awareness are important for preventing Hepatitis B. The purpose of these efforts is to inform the public of the dangers of Hepatitis B, the value of immunisation, and the best practises for preventing transmission. Common methods for raising awareness include using social media, engaging the local community, and forming alliances with healthcare organisations.

Report Scope

Report CoverageDetails
Segments CoveredType, End Use
Regions Covered• North America (United States, Canada, Mexico)  
• Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe)  
Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC)  
• Latin America (Argentina, Brazil, Rest of South America)  
• Middle East & Africa (GCC, South Africa, Rest of MEA)
Company ProfiledAccord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Par Pharmaceutical, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals.

Unlock insights tailored to your business with our bespoke market research solutions - Click to get your customized report now!


Industry Restraints and Challenges:

Huge cost associated in vaccine storage and transportation

The entire cost of distributing hepatitis B vaccines can in fact be increased by transportation problems. To keep them safe and effective, hepatitis B vaccinations need to be handled and transported carefully. Temp changes and physical shocks can affect the efficacy of hepatitis B immunisations. Damage prevention during shipping necessitates special handling and packaging. Costs for packaging supplies and quality assurance procedures can increase as a result. Security measures are sometimes required during shipment because of the value and significance of vaccinations, which makes it possible for them to be stolen or tampered with. Costs for security guards, cameras, and safe conveyance vehicles may be involved.

Report Coverage & Deliverables

Historical Statistics Growth Forecasts Latest Trends & Innovations Market Segmentation Regional Opportunities Competitive Landscape
Hepatitis B Vaccine Market
Hepatitis B Vaccine Market

Regional Forecast:

North American Market

North America region’s Hepatitis B Vaccine market held a 42% business share in 2023. Hepatitis B vaccinations are a crucial component of standard paediatric immunisation programmes in North America. To ensure immunisation, they are often given to infants shortly after birth in a series of doses. Hepatitis B vaccination delivery and distribution are intimately correlated with North American healthcare systems. These vaccinations are frequently distributed by hospitals, clinics, and public health initiatives. Depending on elements including insurance coverage, financial assistance from the government, and vaccination policies of healthcare providers, the cost of hepatitis B vaccines and access to immunisation may change. The availability of the hepatitis B vaccine for everyone, including those at higher risk, has being worked on.

Asia Pacific Market

Asia Pacific is witnessing the fastest market growth between 2024 to 2033. Hepatitis B infections are widespread in the Asia-Pacific area, where several nations have high incidence rates. Hepatitis B vaccine has become heavily promoted as a preventative measure as a result of this. Government-funded immunisation programmes with hepatitis B vaccine are widespread in the Asia-Pacific area. In an effort to offer long-lasting immunity against the virus, these programmes frequently target newborns and young children. The Asia-Pacific market is served by a number of domestic and foreign hepatitis B vaccine producers. Hepatitis B vaccinations are made by a number of regional manufacturers in nations like China and India in addition to big pharmaceutical companies to satisfy local demand.

Get more details on this report -

Segmentation Analysis:

Insights by Type

The combination vaccine segment accounted the largest market share over around 67% in 2023. Hepatitis B is a component of several combination vaccinations that have been created and put on the market. These vaccines offer hepatitis B protection along with defence against other illnesses such hepatitis A, diphtheria, tetanus, pertussis, polio, or Haemophilus influenzae type b (Hib). Combination vaccines increase immunisation rates by providing defence against many illnesses in a single shot. This is crucial in areas with weaker healthcare infrastructure or when treating prevalent diseases requires several immunisations. The hepatitis B market's combination vaccination sector has experienced consistent growth. Pharmaceutical firms have kept up their investments in the creation of fresh combo vaccinations that include hepatitis B defence.

Insights by End Use

The hospitals segment is anticipated to reach USD 4.14 billion, By 2033. The prevalence and incidence of hepatitis B in a specific area or nation have a big impact on how big the market is. Increased hepatitis B infection rates can result in a rise in the need for hospital healthcare services, antiviral drugs, and diagnostic testing. Government-sponsored vaccination campaigns may help to lower hepatitis B cases, which will have an impact on the market. Hospitals may experience a decline in the need for medical services but an increase in the need for vaccinations. The hepatitis B market's treatment segment may develop as a result of the availability of potent antiviral drugs and therapies. Hospital procedures and patient outcomes may be affected by the introduction of new drugs and improvements in treatment plans.

Get more details on this report -

Competitive Landscape:

Major players in the market

  • Accord Healthcare Inc.
  • Apotex Corp.
  • Arbutus Biopharma
  • Arrowhead Pharma
  • Aurobindo Pharma Limited
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Par Pharmaceutical, Inc.
  • Teva Pharmaceuticals
  • Zydus Pharmaceuticals

Our Clients

Why Choose Us

Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.

Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.

Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.

Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.

Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.

Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.

Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.

Select Licence Type

Single User

US$ 4250

Multi User

US$ 5050

Corporate User

US$ 6150

Hepatitis B Vaccine Market Size & Share, by Type (...

RD Code : 24